Hypoxia-induced apoptosis is blocked by adrenomedullin via upregulation of Bcl-2 in human osteosarcoma cells

Wu,Xue-Yuan; Hao,Cui-Pei; Ling,Ming; Guo,Chi-Hua; Ma,Wei

doi:10.3892/or.2015.4011

Hypoxia-induced apoptosis is blocked by adrenomedullin via upregulation of Bcl-2 in human osteosarcoma cells

Authors:
- Xue-Yuan Wu
- Cui-Pei Hao
- Ming Ling
- Chi-Hua Guo
- Wei Ma
View Affiliations

Affiliations: Department of Orthopaedics, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China, Department of Gynaecology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, P.R. China, Department of Orthopedics, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: May 28, 2015 https://doi.org/10.3892/or.2015.4011
Pages: 787-794

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adrenomedullin (ADM), a multifunctional regulatory peptide, is potentially induced by hypoxia in physiological and pathological tissues, including many types of malignant tumors. Recent research has demonstrated that ADM expression is highly associated with the prognosis and disease severity of human osteosarcoma. However, the effect of ADM on the apoptosis of osteosarcoma cells and its possible mechanism remain to be elucidated. In the present study, we observed that mRNA and protein levels of ADM were increased in human osteosarcoma SOSP-F5M2 cells under a hypoxic microenvironment induced by cobalt chloride (CoCl2) in a time-dependent manner. Treatment with ADM significantly blunted hypoxic-induced apoptosis, evaluated by Hoechst 33342 staining and Annexin V-FITC/PI labeling. The expression of B-cell lymphoma-2 (Bcl-2) was increased by administration of ADM; meanwhile, this effect was reversed by exogenously adding U0126, a selective inhibitor of MEK or ADM22-52 (ADM-specific receptor antagonist). These results demonstrated that ADM acted as a survival factor to inhibit hypoxic-induced apoptosis via interacting with its receptors CRLR-RAMP (2,3) in osteosarcoma cells. The anti-apoptotic function of ADM was found to be mediated by upregulation of the expression of Bcl-2 partially through activation of the MEK/ERK1/2 signaling pathway. Therefore, targeting of the ADM/ADM acceptors/ERK1/2/Bcl-2 pathway may provide a potential strategy through which to induce the apoptosis of osteosarcoma cells.

View Figures

View References

1	Cleton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH and Hogendoorn PC: Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer. 101:1909–1918. 2009. View Article : Google Scholar : PubMed/NCBI
2	Zeng W, Wan R, Zheng Y, Singh SR and Wei Y: Hypoxia, stem cells and bone tumor. Cancer Lett. 313:129–136. 2011. View Article : Google Scholar : PubMed/NCBI
3	Zhao N, Sun BC, Sun T, Ma YM, Zhao XL, Liu ZY, Dong XY, Che N, Mo J and Gu Q: Hypoxia-induced vasculogenic mimicry formation via VE-cadherin regulation by Bcl-2. Med Oncol. 29:3599–3607. 2012. View Article : Google Scholar : PubMed/NCBI
4	Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
6	Loges S, Mazzone M, Hohensinner P and Carmeliet P: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell. 15:167–170. 2009. View Article : Google Scholar : PubMed/NCBI
7	Nurwidya F, Takahashi F, Minakata K, Murakami A and Takahashi K: From tumor hypoxia to cancer progression: The implications of hypoxia-inducible factor-1 expression in cancers. Anat Cell Biol. 45:73–78. 2012. View Article : Google Scholar : PubMed/NCBI
8	Dai ZJ, Gao J, Ma XB, Yan K, Liu XX, Kang HF, Ji ZZ, Guan HT and Wang XJ: Up-regulation of hypoxia inducible factor-1α by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells. J Exp Clin Cancer Res. 31:282012. View Article : Google Scholar
9	Knowles HJ, Schaefer KL, Dirksen U and Athanasou NA: Hypoxia and hypoglycaemia in Ewing’s sarcoma and osteosarcoma: Regulation and phenotypic effects of hypoxia-inducible factor. BMC Cancer. 10:3722010. View Article : Google Scholar
10	El Naggar A, Clarkson P, Zhang F, Mathers J, Tognon C and Sorensen PH: Expression and stability of hypoxia inducible factor 1α in osteosarcoma. Pediatr Blood Cancer. 59:1215–1222. 2012. View Article : Google Scholar : PubMed/NCBI
11	Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li Y, Banerjee S, Padhye S and Sarkar FH: Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One. 7:e437262012. View Article : Google Scholar : PubMed/NCBI
12	Dai X, Ma W, He XJ and Jha RK: Elevated expression of adrenomedullin is correlated with prognosis and disease severity in osteosarcoma. Med Oncol. 30:3472013. View Article : Google Scholar
13	Hay DL, Walker CS and Poyner DR: Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: Opportunities and challenges. Endocr Relat Cancer. 18:C1–C14. 2011. View Article : Google Scholar
14	Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H and Eto T: Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 192:553–560. 1993. View Article : Google Scholar : PubMed/NCBI
15	Nikitenko LL, Fox SB, Kehoe S, Rees MC and Bicknell R: Adrenomedullin and tumour angiogenesis. Br J Cancer. 94:1–7. 2006. View Article : Google Scholar
16	Dai X, Ma W, Jha RK and He X: Adrenomedullin and its expression in cancers and bone. A literature review. Front Biosci (Elite Ed). 2:1073–1080. 2010. View Article : Google Scholar
17	Kaseta MK, Khaldi L, Gomatos IP, Tzagarakis GP, Alevizos L, Leandros E, Papagelopoulos PJ and Soucacos PN: Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. J Surg Oncol. 97:259–266. 2008. View Article : Google Scholar
18	Cory S, Huang DC and Adams JM: The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene. 22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
19	Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini SP, Alberghini M, Versari M and Bacci G: Evaluation of P-glyco-protein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 100:1936–1942. 2004. View Article : Google Scholar : PubMed/NCBI
20	Li Z, Takeuchi S, Ohara N and Maruo T: Paradoxically abundant expression of Bcl-2 and adrenomedullin in invasive cervical squamous carcinoma. Int J Clin Oncol. 8:83–89. 2003. View Article : Google Scholar : PubMed/NCBI
21	Oehler MK, Norbury C, Hague S, Rees MC and Bicknell R: Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: A possible promotion mechanism for tumour growth. Oncogene. 20:2937–2945. 2001. View Article : Google Scholar : PubMed/NCBI
22	Park SC, Yoon JH, Lee JH, Yu SJ, Myung SJ, Kim W, Gwak GY, Lee SH, Lee SM, Jang JJ, et al: Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. Cancer Lett. 271:314–322. 2008. View Article : Google Scholar : PubMed/NCBI
23	Abasolo I, Montuenga LM and Calvo A: Adrenomedullin prevents apoptosis in prostate cancer cells. Regul Pept. 133:115–122. 2006. View Article : Google Scholar
24	Chen X, Yang TT, Wang W, Sun HH, Ma BA, Li CX, Ma Q, Yu Z and Fan QY: Establishment and characterization of human osteosarcoma cell lines with different pulmonary metastatic potentials. Cytotechnology. 61:37–44. 2009. View Article : Google Scholar : PubMed/NCBI
25	Ramachandran V, Arumugam T, Hwang RF, Greenson JK, Simeone DM and Logsdon CD: Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res. 67:2666–2675. 2007. View Article : Google Scholar : PubMed/NCBI
26	Martínez A, Vos M, Guédez L, Kaur G, Chen Z, Garayoa M, Pío R, Moody T, Stetler-Stevenson WG, Kleinman HK, et al: The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst. 94:1226–1237. 2002. View Article : Google Scholar : PubMed/NCBI
27	Chen P, Pang X, Zhang Y and He Y: Effect of inhibition of the adrenomedullin gene on the growth and chemosensitivity of ovarian cancer cells. Oncol Rep. 27:1461–1466. 2012.PubMed/NCBI
28	Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H and Tsujimoto Y: Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature. 374:811–813. 1995. View Article : Google Scholar : PubMed/NCBI
29	Wu X, Cai ZD, Lou LM and Zhu YB: Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiol. 36:212–216. 2012. View Article : Google Scholar
30	Zhao Y, Zhang CL, Zeng BF, Wu XS, Gao TT and Oda Y: Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun. 390:642–647. 2009. View Article : Google Scholar : PubMed/NCBI
31	Ramos JW: The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 40:2707–2719. 2008. View Article : Google Scholar : PubMed/NCBI
32	Atabakhsh E and Schild-Poulter C: RanBPM is an inhibitor of ERK signaling. PLoS One. 7:e478032012. View Article : Google Scholar : PubMed/NCBI
33	Deville JL, Salas S, Figarella-Branger D, Ouafik L and Daniel L: Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin Ther Targets. 14:1059–1072. 2010. View Article : Google Scholar : PubMed/NCBI
34	Uzan B, Villemin A, Garel JM and Cressent M: Adrenomedullin is anti-apoptotic in osteoblasts through CGRP1 receptors and MEK-ERK pathway. J Cell Physiol. 215:122–128. 2008. View Article : Google Scholar
35	Vacotto M, Coso O and Fiszer de Plazas S: Programmed cell death and differential JNK, p38 and ERK response in a prenatal acute hypoxic hypoxia model. Neurochem Int. 52:857–863. 2008. View Article : Google Scholar
36	Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
37	Hers I, Vincent EE and Tavaré JM: Akt signalling in health and disease. Cell Signal. 23:1515–1527. 2011. View Article : Google Scholar : PubMed/NCBI
38	Zambon AC, Wilderman A, Ho A and Insel PA: Increased expression of the pro-apoptotic protein BIM, a mechanism for cAMP/protein kinase A (PKA)-induced apoptosis of immature T cells. J Biol Chem. 286:33260–33267. 2011. View Article : Google Scholar : PubMed/NCBI
39	Nagaya N, Mori H, Murakami S, Kangawa K and Kitamura S: Adrenomedullin: Angiogenesis and gene therapy. Am J Physiol Regul Integr Comp Physiol. 288:R1432–R1437. 2005. View Article : Google Scholar : PubMed/NCBI